

**PCR-/NAT *Pneumocystis jirovecii*
 (RV 560) Mai 2016**



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.
Sample composition and expected results.

	<i>Erwartet / expected</i>		<i>Probenzusammensetzung / Sample composition</i>
1615601	+++	61	<i>Pneumocystis jirovecii</i> (~ 1x10 ⁶ organisms /mL)
1615602	∅	62	<i>Escherichia coli</i> K12
1615603	++	61	<i>Pneumocystis jirovecii</i> (~ 1x10 ⁵ organisms /mL)
1615604	(+)	61	<i>Pneumocystis jirovecii</i> (~ 1x10 ⁴ organisms /mL)

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.
Absolute numbers of reported individual results.

<i>n = 90</i>	<i>Probennummer (Sample no.)</i>				<i>Inhibition</i>				
<i>Befund Result</i>	1615601	1615602	1615603	1615604	1615601	1615602	1615603	1615604	
Positiv	89	1	89	84	n.d.	0	0	0	0
Negativ	1	89	1	6	nein no	90	90	90	90
Fraglich Questionable	0	0	0	0	ja yes	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwenden verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number *)	NAT richtig positiv <i>True positive results</i>			NAT richtig negativ <i>True negative results</i>		
	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%
TIB Molbiol LightMix PJ [21] (n =11)	33	33 / 33	100	11	11 / 11	100
r-Biopharm RIDAGENE PJ [22] (n =20)	58	58 / 60	97	20	20 / 20	100
AmpliGnost PJ PCR Kit [23] (n =7)	21	21 / 21	100	7	7 / 7	100
Sacace PJ RealTM [24] (n =3)	9	9 / 9	100	3	3 / 3	100
Commercial assay / kit [27] (n =10)	30	30 / 30	100	10	10 / 10	100
In house PCR assay [28] (n = 37)	105	105 / 111	95	36	36 / 37	97
Andere / k.A. / other [29] (n = 2)	6	6 / 6	100	2	2 / 2	100

Comments: ¹⁾ As sample #1615604 contained a low number of *Pneumocystis jirovecii* target organisms, negative PCR results were not rated “false negative” in this EQAS distribution.